Stryker (SYK): Analyst Target at $365 Points to +19% Upside
Key Takeaways
- The central $365 stock price target is the arithmetic mean of the verified analyst price targets reviewed, rounded to a clean level from an underlying average near $363.
- With shares trading around $307, reaching $365 implies roughly 19% upside, a substantial move from current levels.
- Individual analyst price targets span a wide range, from roughly $298 to $465, reflecting meaningful disagreement about valuation and the pace of recovery.
- The strongest supporting factors are resilient underlying demand, record robotics installations, and intact full-year growth guidance.
- The biggest risks are the unresolved peripheral-vascular supply disruption, the resulting securities-fraud investigations, and a premium valuation.
- You can find more on the company's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- For a broader view of the market, explore Trending AI Robots to see AI-driven trading ideas across thousands of tickers.
Analyst Price Targets and Consensus View
Across roughly 30 current analyst price targets reviewed from firms including Barclays ($375), Canaccord Genuity ($385), J.P. Morgan ($400), Wells Fargo ($418), Needham ($418), Goldman Sachs ($357), Truist ($330), BMO Capital ($317), BTIG ($316) and Bernstein ($465), the arithmetic mean sits near $363, which rounds to a $365 central target. The low-to-high range of approximately $298 to $465 is unusually wide, a sign that analysts disagree on both the near-term impact of the supply issue and the appropriate valuation multiple. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The consensus view is broadly constructive but has cooled. Following the September disclosure that a peripheral-vascular manufacturing problem would persist into the fourth quarter, several firms trimmed targets and shifted to more cautious language, while others retained Buy or Outperform ratings, citing a diversified portfolio and long-term growth drivers. These targets typically reflect a research horizon of around 12 months and are estimates, not guarantees.
Current Market Position and Path Toward the Target
At approximately $307, the stock trades well below its 52-week high near $389 but above its 52-week low near $267. Reaching $365 requires an advance of roughly 19%, a substantial move that would require both an operational recovery and a re-rating of sentiment. The most likely path is gradual: confirmation that the supply disruption is resolving, followed by earnings beats and upward estimate revisions that restore investor confidence in the company's growth premium.
What Could Support a Move Toward the Target
Underlying demand remains firm. Second-quarter results showed adjusted EPS of $3.69 versus a $3.49 consensus, revenue up 9.4% year over year, and organic growth near 9% even with the supply drag. Orthopaedics and MedSurg grew organically at roughly 8% to 9%, and management cited record Mako robotic-system installations. Full-year growth guidance of approximately 8.3% to 9.3% remains intact. Recent additions such as the ZuriMED acquisition and an FDA-cleared Apple Vision Pro surgical application reinforce the company's digital-surgery and portfolio-expansion strategy. At roughly 20 times forward earnings, some analysts argue the stock trades at a discounted premium relative to medtech peers. From what I see, Tickeron’s AI Trend Prediction Engine highlights the resilience in these fundamentals.
What Could Prevent the Target From Being Reached
The central obstacle is the peripheral-vascular supply disruption, which management now expects to persist into the fourth quarter and which trimmed an estimated 70 to 80 basis points from recent growth. The disclosure that contradicted earlier assurances triggered an 8.8% single-day decline and prompted securities-fraud investigations by several plaintiff law firms, although no case has been filed. A premium valuation leaves little room for disappointment, and any further guidance cuts, slower procedure volumes, or an extended legal overhang could keep the stock range-bound below $365.
Technical Levels and Market Structure
The shares remain in a longer-term uptrend that stalled in 2026. The 52-week low near $267 to $270 is a key support level, while resistance sits near $330 and again near the 52-week high around $389. A decisive close above the $330 area would signal improving momentum, while a break below $267 would mark a new multi-month low and undermine the recovery case. I’m watching this closely with Tickeron’s AI Real Time Patterns for any early shifts in momentum.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month outlook, though individual firms vary. The next earnings release, scheduled for late October, is the most important catalyst: investors will watch for commentary on whether the supply issue is normalizing, the magnitude of any backorder recovery, and any change to full-year guidance. Additional items to monitor include analyst target revisions, procedure-volume data across the medtech sector, regulatory and legal developments, and interest-rate and macroeconomic conditions that influence healthcare spending.
Final Assessment
The $365 target represents the average of current analyst price targets and implies roughly 19% upside from about $307. Support comes from resilient underlying demand, record robotics adoption, and intact growth guidance, while the unresolved supply disruption, the securities-fraud investigations, and a premium valuation are the principal obstacles. The wide $298-to-$465 analyst range underscores genuine disagreement about how quickly the company can restore credibility and growth. Whether SYK reaches $365 will likely depend first on the upcoming earnings report and clear evidence that the supply issue is finally behind it; no outcome is guaranteed.
AI Daily Buy/Sell Signals
In my own analysis, I frequently review Tickeron’s AI Daily Buy/Sell Signals to stay on top of shifting conditions for names like this. The tool applies artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals drawn from technical behavior and market changes. It has helped me spot potential turning points more efficiently alongside traditional research, particularly during periods of volatility around supply issues or earnings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
SYK in +3.21% Uptrend, advancing for three consecutive days on October 23, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SYK advanced for three days, in 171 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on SYK as a result. In 49 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
The Moving Average Convergence Divergence (MACD) for SYK just turned positive on September 28, 2026. Looking at past instances where SYK's MACD turned positive, the stock continued to rise in 21 of 44 cases over the following month. The odds of a continued upward trend are 48%.
SYK moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The Aroon Indicator entered an Uptrend today. In 128 of 258 cases where SYK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
SYK broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 75 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.911) is normal, around the industry mean (2.906). P/E Ratio (31.567) is within average values for comparable stocks, (2.003). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.052). Dividend Yield (0.011) settles around the average of (0.009) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of reconstructive, medical and surgical, and neurotechnology and spine products
Industry MedicalNursingServices
Advertisement